Pennant Group Inc is expected to report Q3 2026 revenue of $299.47 million and normalized EPS of $0.35, while the stock currently trades at $41.66 relative to a $46.83 average analyst price target.
Investors are primarily focused on the Hospice Average Daily Census (ADC), which serves as the leading indicator for organic volume growth and the effective integration of recent acquisitions.
The company enters the report following a significant upward revision to its full-year 2026 guidance, driven by robust home health admissions and improving clinical quality metrics. Market participants will also be monitoring labor cost management and the impact of the finalized Medicare reimbursement rates for the 2027 fiscal year.